Evidence map›Paper›PMID 40800215›Full record

ArticleHealth behavior research2024

The challenges of investigating derived psychoactive cannabis product brand quality: Using a popular brand as an example.

Cassidy R LoParco, Zachary L Prater, Doug Henry

Abstract read
In one paragraph

Article in Health behavior research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Cassidy R LoParcoGeorge Washington University.
Zachary L PraterUniversity of North Texas.
Doug HenryUniversity of North Texas.

Funding

Helping Everyone Achieve a LifeTime of Health - Future Addiction Scientist TrainingR25DA054015 · NIDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI OBASI, EZEMENARI M., REITZEL, LORRAINE R · 2021 to 2025
$1.0M
Socio-structural determinants of cannabis and derived psychoactive cannabis product use and consequences among young adultsF32DA060612 · NIDA · GEORGE WASHINGTON UNIVERSITY · PI LOPARCO, CASSIDY R · 2024 to 2025
$101k
NIDA NIH HHS F32 DA060612NIDA NIH HHS R25 DA054015
6 · The paper itself

Abstract

With widely divergent state and federal regulations and a history of suspect brands and illicit markets, derived psychoactive cannabis products (DPCPs) face contested discourse as to their content, quality, and safety. We conducted exploratory research on public-health related factors related to brand quality including assessing potential counterfeit products, website and social media presence, third party laboratory testing, distribution practices, and consumer experiences on social media. Findings indicate the difficulty consumers face in finding information related to DPCP brands, and the questionable quality of popularly branded products. We recommend regulation and oversight to ensure product safety.

Indexed as

brandderived psychoactive cannabis productshemp-derived cannabinoidsqualityregulation

Identifiers

PMID40800215
PMCPMC12341808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.